Zhong-Yin Zhang

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 30

Top Topics

Mass Spectrometry

Protein Protein

Metastatic Breast Cancer

Top Venues

Journal of medicinal chemistry

Expert opinion on therapeutic targets

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Jinmin Miao, Zhong-Yin Zhang
Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation. ChemMedChem 19 (7) (2024)
Shiyu Xiao, Hongxia Chen, Yunpeng Bai, Zhong-Yin Zhang, Yan Liu
Targeting PRL phosphatases in hematological malignancies. Expert opinion on therapeutic targets 28 (4) (2024)
Shiyu Xiao, Hongxia Chen, Yunpeng Bai, Zhong-Yin Zhang, Yan Liu
Targeting PRL phosphatases in hematological malignancies. Expert opinion on therapeutic targets (2024)
Jiajun Dong, Brenson A Jassim, Kedric L Milholland, Zihan Qu, Yunpeng Bai, Yiming Miao, Jinmin Miao, Yuan Ma, Jianping Lin, Mark C Hall, Zhong-Yin Zhang
Development of Novel Phosphonodifluoromethyl-Containing Phosphotyrosine Mimetics and a First-In-Class, Potent, Selective, and Bioavailable Inhibitor of Human CDC14 Phosphatases. Journal of medicinal chemistry 67 (11) (2024)
Jinmin Miao, Zhong-Yin Zhang
Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation. ChemMedChem (2024)
Shiyu Xiao, Hongxia Chen, Yunpeng Bai, Zhong-Yin Zhang, Yan Liu
Targeting PRL phosphatases in hematological malignancies. Expert opinion on therapeutic targets 28 (4) (2024)
Jinmin Miao, Zhong-Yin Zhang
Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation. ChemMedChem 19 (7) (2024)
Shiyu Xiao, Hongxia Chen, Yunpeng Bai, Zhong-Yin Zhang, Yan Liu
Targeting PRL phosphatases in hematological malignancies. Expert opinion on therapeutic targets (2024)
Jinmin Miao, Zhong-Yin Zhang
Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation. ChemMedChem 19 (7) (2024)
Jiajun Dong, Brenson A Jassim, Kedric L Milholland, Zihan Qu, Yunpeng Bai, Yiming Miao, Jinmin Miao, Yuan Ma, Jianping Lin, Mark C Hall, Zhong-Yin Zhang
Development of Novel Phosphonodifluoromethyl-Containing Phosphotyrosine Mimetics and a First-In-Class, Potent, Selective, and Bioavailable Inhibitor of Human CDC14 Phosphatases. Journal of medicinal chemistry (2024)
Jinmin Miao, Zhong-Yin Zhang
Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation. ChemMedChem 19 (7) (2024)
Frederick Nguele Meke, Yunpeng Bai, Diego Ruiz-Avila, Colin Carlock, Jinan Ayub, Jinmin Miao, Yanyang Hu, Qinglin Li, Zhong-Yin Zhang
Inhibition of PRL2 upregulates PTEN and attenuates tumor growth in Tp53-deficient sarcoma and lymphoma mouse models. Cancer research communications (2023)
Jinmin Miao, Jiajun Dong, Yiming Miao, Yunpeng Bai, Zihan Qu, Brenson A Jassim, Bo Huang, Quyen D Nguyen, Yuan Ma, Allison A Murray, Jinyue Li, Philip S Low, Zhong-Yin Zhang
Discovery of a selective TC-PTP degrader for cancer immunotherapy. Chemical science 14 (44) (2023)
Hongxia Chen, Yunpeng Bai, Michihiro Kobayashi, Shiyu Xiao, Sergio Barajas, Wenjie Cai, Sisi Chen, Jinmin Miao, Frederick Nguele Meke, Chonghua Yao, Yuxia Yang, Katherine Strube, Odelia Satchivi, Jianmin Sun, Lars Rönnstrand, James M Croop, H Scott Boswell, Yuzhi Jia, Huiping Liu, Loretta S Li, Jessica K Altman, Elizabeth A Eklund, Madina Sukhanova, Peng Ji, Wei Tong, Hamid Band, Danny T Huang, Leonidas C Platanias, Zhong-Yin Zhang, Yan Liu
PRL2 phosphatase promotes oncogenic KIT signaling in leukemia cells through modulating CBL phosphorylation. Molecular cancer research : MCR (2023)
Shuwei Liang, Eric Tran, Xin Du, Jiajun Dong, Harrison Sudholz, Hao Chen, Zihan Qu, Nicholas D Huntington, Jeffrey J Babon, Nadia J Kershaw, Zhong-Yin Zhang, Jonathan B Baell, Florian Wiede, Tony Tiganis
A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity. Nature communications 14 (1) (2023)
Manxi Yang, Daisy M Unsihuay Vila, Hang Hu, Frederick Nguele Meke, Zihan Qu, Zhong-Yin Zhang, Julia Laskin
Nano-DESI Mass Spectrometry Imaging of Proteoforms in Biological Tissues with High Spatial Resolution. Analytical chemistry (2023)
Jinmin Miao, Yunpeng Bai, Yiming Miao, Zihan Qu, Jiajun Dong, Ruo-Yu Zhang, Devesh Aggarwal, Brenson A Jassim, Quyen Nguyen, Zhong-Yin Zhang
Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity. Molecules (Basel, Switzerland) 28 (19) (2023)
Brenson A Jassim, Jianping Lin, Zhong-Yin Zhang
PTPN22: structure, function, and developments in inhibitor discovery with applications for immunotherapy. Expert opinion on drug discovery 17 (8) (2022)
Rongjun He, Jifeng Wang, Zhi-Hong Yu, Julie S Moyers, M Dodson Michael, Timothy B Durham, Jeff W Cramer, Yuewei Qian, Amy Lin, Li Wu, Nicholas Noinaj, David G Barrett, Zhong-Yin Zhang
Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors. Journal of medicinal chemistry 65 (20) (2022)
Aaron D Krabill, Zhong-Yin Zhang
Functional interrogation and therapeutic targeting of protein tyrosine phosphatases. Biochemical Society transactions 49 (4) (2022)
Peipei Zhu, Xiaofeng Wu, Ruo-Yu Zhang, Chuan-Chih Hsu, Zhong-Yin Zhang, Weiguo Andy Tao
An Integrated Proteomic Strategy to Identify SHP2 Substrates. Journal of proteome research 21 (10) (2022)
Teklab Gebregiworgis, Yoshihito Kano, Jonathan St-Germain, Nikolina Radulovich, Molly L Udaskin, Ahmet Mentes, Richard Huang, Betty P K Poon, Wenguang He, Ivette Valencia-Sama, Claire M Robinson, Melissa Huestis, Jinmin Miao, Jen Jen Yeh, Zhong-Yin Zhang, Meredith S Irwin, Jeffrey E Lee, Ming Sound Tsao, Brian Raught, Christopher B Marshall, Michael Ohh, Mitsuhiko Ikura
The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. Nature communications 12 (1) (2021)
Brenda Medellin, Wanjie Yang, Srihari Konduri, Jiajun Dong, Seema Irani, Haoyi Wu, Wendy L Matthews, Zhong-Yin Zhang, Dionico Siegel, Yan Jessie Zhang
Targeted Covalent Inhibition of Small CTD Phosphatase 1 to Promote the Degradation of the REST Transcription Factor in Human Cells. Journal of medicinal chemistry 65 (1) (2021)
Qinglin Li, Yunpeng Bai, L Tiffany Lyle, Guimei Yu, Ovini Amarasinghe, Frederick Nguele Meke, Colin Carlock, Zhong-Yin Zhang
Mechanism of PRL2 phosphatase-mediated PTEN degradation and tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 117 (34) (2020)
Hao Chen, Sarah Libring, Kasi Viswanatharaju Ruddraraju, Jinmin Miao, Luis Solorio, Zhong-Yin Zhang, Michael K Wendt
SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer. Oncogene 39 (49) (2020)
Kasi Viswanatharaju Ruddraraju, Devesh Aggarwal, Zhong-Yin Zhang
Therapeutic Targeting of Protein Tyrosine Phosphatases from Mycobacterium tuberculosis. Microorganisms 9 (1) (2020)
Kasi Viswanatharaju Ruddraraju, Devesh Aggarwal, Congwei Niu, Erica Anne Baker, Ruo-Yu Zhang, Li Wu, Zhong-Yin Zhang
Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium tuberculosis Protein Tyrosine Phosphatase B. Journal of medicinal chemistry 63 (17) (2020)
Dexter C Davis, Dominic G Hoch, Li Wu, Daniel Abegg, Brandon S Martin, Zhong-Yin Zhang, Alexander Adibekian, Mingji Dai
Total Synthesis, Biological Evaluation, and Target Identification of Rare Abies Sesquiterpenoids. Journal of the American Chemical Society 140 (50) (2018)
Zhi-Hong Yu, Zhong-Yin Zhang
Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases. Chemical reviews 118 (3) (2017)
Zhong-Yin Zhang
Drugging the Undruggable: Therapeutic Potential of Targeting Protein Tyrosine Phosphatases. Accounts of chemical research 50 (1) (2016)